|
Sign In to gain access to subscriptions and/or personal tools.
|
Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial
Markus Gaubitz
Department of Medicine B, University of Minster, Minster, Germany; gaubitz{at}uni-muenster.de
Annette Schorat
Heiko Schottel
Department of Medicine B, University of Minster, Minster, Germany
Peter Kern
University of Erlangen-Nirnberg, Erlangen, Germany
Wolfram Domschke
Department of Medicine B, University of Minster, Minster, Germany
Objective: To investigate the effectiveness and safety of mycophenolate mofetil in patients with systemic lupus erythematosus who were inadequately controlled with corticosteroids, antimalarials, and other immunosuppresive agents.
Methods: Ten patients with systemic lupus erythematosus (SLE) were treated with 1500-2000 mg mycophenolae mofetil (MMF) daily for a median observation time of 11.2 ± 2.4 (8-16) months in an open clinical trial. The effectiveness and safety of treatment were analyzed using an established disease activity score, clinical status, and laboratory parameters.
Results: All patients improved under treatment with no or only minor side effects. The disease activity score (SLAM) decreased statistically significantly from a median of 15.6 ± 5.5 to 9.9 ± 4.1 after three months (P < 0.01) and to 8.0 ± 3.3 after six months (P < 0.01). Hematologic parameters did not change significantly whereas a reduction of inflammatory markers was observed. Four patients with SLE-nephritis already treated with cyclophosphamide pulse therapy continuously showed a slight improvement of renal function. Prednisolone dosages could be reduced significantly from a median level of 10.0+ 5.1 mg/d before treatment to 4.6 ±3.5 mg/d after six months (P < 0.01).
Conclusion: Mycophenolate mofetil is a promising option in immunosuppressive treatment of patients with moderate and severe systemic lupus erythematosus who did not show a satisfactory response to other immunosuppressives.
Key Words: systemic lupus erythematosus • mycophenolate mofetil • treatment • immunosuppression
Lupus, Vol. 8, No. 9,
731-736 (1999)
DOI: 10.1191/096120399678840927
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
C Nannini, C. Crowson, E. Matteson, and K. Moder
Mycophenolate mofetil is effective in reducing disease flares in systemic lupus erythematosus patients: a retrospective study
Lupus,
April 1, 2009;
18(5):
394 - 399.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Vento, A. Perez Aytes, A. Ledo, V. Boso, and J. C. Carey
Mycophenolate Mofetil During Pregnancy: Some Words of Caution
Pediatrics,
July 1, 2008;
122(1):
184 - 185.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. Wang, W. Hu, H. Xie, H. Zhang, H. Chen, C. Zeng, Z. Liu, and L. Li
Induction therapies for class IV lupus nephritis with non-inflammatory necrotizing vasculopathy: mycophenolate mofetil or intravenous cyclophosphamide
Lupus,
September 1, 2007;
16(9):
707 - 712.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Walsh, M. James, D. Jayne, M. Tonelli, B. J. Manns, and B. R. Hemmelgarn
Mycophenolate Mofetil for Induction Therapy of Lupus Nephritis: A Systematic Review and Meta-Analysis
Clin. J. Am. Soc. Nephrol.,
September 1, 2007;
2(5):
968 - 975.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Falcini and F. Nacci
Review: Systemic lupus erythematosus in the young: the importance of a transition clinic
Lupus,
August 1, 2007;
16(8):
613 - 617.
[Abstract]
[PDF]
|
|
|
|
|
|
|
B. Zhu, N. Chen, Y. Lin, H. Ren, W. Zhang, W. Wang, X. Pan, and H. Yu
Mycophenolate mofetil in induction and maintenance therapy of severe lupus nephritis: a meta-analysis of randomized controlled trials
Nephrol. Dial. Transplant.,
July 1, 2007;
22(7):
1933 - 1942.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A Doria, L Iaccarino, S Arienti, M E Rampudda, M G Canova, R Rondinone, and S Todesco
Mycophenolate mofetil and systemic lupus erythematosus
Lupus,
November 1, 2006;
15(11_suppl):
44 - 54.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M A Dooley
Mycophenylate mofetil: what role in the treatment of lupus?
Lupus,
March 1, 2006;
15(3):
179 - 182.
[Abstract]
[PDF]
|
|
|
|
|
|
|
W. D Cahoon Jr and D. R Kockler
Mycophenolate Mofetil Treatment of Myasthenia Gravis
Ann. Pharmacother.,
February 1, 2006;
40(2):
295 - 298.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Ginzler, M. A. Dooley, C. Aranow, M. Y. Kim, J. Buyon, J. T. Merrill, M. Petri, G. S. Gilkeson, D. J. Wallace, M. H. Weisman, et al.
Mycophenolate Mofetil or Intravenous Cyclophosphamide for Lupus Nephritis.
N. Engl. J. Med.,
November 24, 2005;
353(21):
2219 - 2228.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C N Pisoni, Y Karim, and M J Cuadrado
Mycophenolate mofetil and systemic lupus erythematosus: an overview
Lupus,
March 1, 2005;
14(3_suppl):
s9 - s11.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Hartmann and A Enk
Mycophenolate mofetil and skin diseases
Lupus,
March 1, 2005;
14(3_suppl):
s58 - s63.
[Abstract]
[PDF]
|
|
|
|
|
|
|
H. Sayarlioglu, R. Erkoc, E. Dogan, M. Sayarlioglu, and C. Topal
Mycophenolate mofetil use in hepatitis B associated-membranous and membranoproliferative glomerulonephritis induces viral replication
Ann. Pharmacother.,
March 1, 2005;
39(3):
573 - 573.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E M Ginzler and C Aranow
Mycophenolate mofetil in lupus nephritis
Lupus,
January 1, 2005;
14(1):
59 - 64.
[Abstract]
[PDF]
|
|
|
|
|
|
|
C. Pisoni, Y. Karim, and M. Cuadrado
Mycophenolate mofetil and systemic lupus erythematosus: an overview
Lupus,
January 1, 2005;
14(1_suppl):
s9 - s11.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M. Hartmann and A. Enk
Mycophenolate mofetil and skin diseases
Lupus,
January 1, 2005;
14(1_suppl):
s58 - s63.
[Abstract]
[PDF]
|
|
|
|
|
|
|
F Falcini
Vascular and connective tissue diseases in the paediatric world
Lupus,
February 1, 2004;
13(2):
77 - 84.
[Abstract]
[PDF]
|
|
|
|
|
|
|
L. Ding, M. Zhao, W. Zou, Y. Liu, and H. Wang
Mycophenolate mofetil combined with prednisone for diffuse proliferative lupus nephritis: a histopathological study
Lupus,
February 1, 2004;
13(2):
113 - 118.
[Abstract]
[PDF]
|
|
|
|
|
|
|
M Bijl, G Horst, H Bootsma, P C Limburg, and C G M Kallenberg
Mycophenolate mofetil prevents a clinical relapse in patients with systemic lupus erythematosus at risk
Ann Rheum Dis,
June 1, 2003;
62(6):
534 - 539.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Zatz, I. L. Noronha, and C. K. Fujihara
Experimental and clinical rationale for use of MMF in nontransplant progressive nephropathies
Am J Physiol Renal Physiol,
December 1, 2002;
283(6):
F1167 - F1175.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. M. Hanjani and C. H. Nousari
Mycophenolate Mofetil for the Treatment of Cutaneous Lupus Erythematosus With Smoldering Systemic Involvement
Arch Dermatol,
December 1, 2002;
138(12):
1616 - 1618.
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Y. Karim, P. Alba, M.-J. Cuadrado, I. C. Abbs, D. P. D'Cruz, M. A. Khamashta, and G. R. V. Hughes
Mycophenolate mofetil for systemic lupus erythematosus refractory to other immunosuppressive agents
Rheumatology,
August 1, 2002;
41(8):
876 - 882.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Nieto, E. Escudero, E. Navarro, M. Yanez-Mo, A. Martin, G. Perez de Lema, F. Sanchez-Madrid, and F. Mampaso
Effects of Mycophenolate Mofetil in Mercury-Induced Autoimmune Nephritis
J. Am. Soc. Nephrol.,
April 1, 2002;
13(4):
937 - 945.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D Adu, J Cross, and D R. Jayne
Treatment of systemic lupus erythematosus with mycophenolate mofetil
Lupus,
March 1, 2001;
10(3):
203 - 208.
[Abstract]
[PDF]
|
|
|
|
|
|
|
V. Chaudhry, D. R. Cornblath, J. W. Griffin, R. O'Brien, and D. B. Drachman
Mycophenolate mofetil: A safe and promising immunosuppressant in neuromuscular diseases
Neurology,
January 9, 2001;
56(1):
94 - 96.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J Cross and D Jayne
Mycophenolate mofetil in lupus nephritis
Lupus,
November 1, 2000;
9(9):
647 - 650.
[PDF]
|
|
|
|
|
